Mobic

Mobic Information

Brand Name: Mobic

Generic Name: Meloxicam

Other Common Names: Movicox

Mobic (meloxicam) is used to relieve the signs and symptoms of osteoarthritis in adults.

It is a nonsteroidal anti-inflammatory drug (Anti-Inflammatory Drugs">NSAID).

Mobic (meloxicam), an oxicam derivative, is a member of the enolic acid group of nonsteroidal anti-inflammatory drugs (Anti-Inflammatory Drugs">NSAIDs). Each yellow tablet contains meloxicam 7.5 mg for oral administration.

Mobic Ingredients and Composition

Mobic Structural Formula and Composition

How To Take Mobic and Mobic Dosage and Administration

The lowest dose of Mobic should be sought for each patient. For the treatment of osteoarthritis the recommended starting and maintenance dose of Mobic is 7.5 mg once daily. Some patients may receive additional benefit by increasing the dose to 15 mg once daily. The maximum recommended daily dose of Mobic is 15 mg.

Mobic may be taken without regard to timing of meals.

If you suspect a Mobic Overdose

Symptoms of overdose may include:

nausea
sluggishness
severe stomach pain
coffee ground-like vomit
dark stool

Mobic Side Effects

Mobic Precautions and Contraindications

Inform your doctor of any other medical conditions including asthma, nasal polyps, any allergies - especially aspirin/Anti-Inflammatory Drugs">NSAID allergy (e.g., ibuprofen, celecoxib), pregnancy, or breast-feeding.

Do not take this drug if you ever had any unusual or allergic reaction to aspirin, ibuprofen, naproxen, or any other medicine used to treat pain, fever, swelling, or arthritis.

This drug may cause dizziness, thus you should not drive, operate machinery, or do anything else that could be dangerous until you know how you react to this medicine.

This drug may cause increased sensitivity to the sun. Avoid exposure to the sun or sunlamps until you know how you react to this medicine. Use a sunscreen or protective clothing if you must be outside for a prolonged period.

Do not mix alcohol with Mobic, unless you first discuss it with your doctor.

Detailed Precautions

Mobic Drug Interactions

Some drugs that may interact with Mobic include other Anti-Inflammatory Drugs">NSAIDs aspirin, naproxen (brand names Aleve, Naprosyn) and ibuprofen (Advil, Motrin).

Other drugs that may interact include:

warfarin (Coumadin)
lithium (Lithobid)
fluconazole (Diflucan)
furosemide (Lasix)
enalapril (Vasotec)
lisinopril (Zestril)

ACE inhibitors

Reports suggest that Anti-Inflammatory Drugs">NSAIDs may diminish the antihypertensive effect of angiotensin-converting enzyme (ACE) inhibitors. This interaction should be given consideration in patients taking Anti-Inflammatory Drugs">NSAIDs concomitantly with ACE inhibitors.

Aspirin

Concomitant administration of aspirin (1000 mg TID) to healthy volunteers tended to increase the AUC (10%) and C_max (24%) of meloxicam. The clinical significance of this interaction is not known; however, as with other Anti-Inflammatory Drugs">NSAIDs, concomitant administration of meloxicam and aspirin is not generally recommended because of the potential for increased adverse effects. Concomitant administration of low-dose aspirin with Mobic may result in an increased rate of GI ulceration or other complications, compared to use of Mobic alone. Mobic is not a substitute for aspirin for cardiovascular prophylaxis.

Cholestyramine

Pretreatment for four days with cholestyramine significantly increased the clearance of meloxicam by 50%. This resulted in a decrease in t1/2, from 19.2 hours to 12.5 hours, and a 35% reduction in AUC. This suggests the existence of a recirculation pathway for meloxicam in the gastrointestinal tract. The clinical relevance of this interaction has not been established.

Cimetidine

Concomitant administration of 200 mg cimetidine QID did not alter the single-dose pharmacokinetics of 30 mg meloxicam.

Digoxin

Meloxicam 15 mg once daily for 7 days did not alter the plasma concentration profile of digoxin after b-acetyldigoxin administration for 7 days at clinical doses. In vitro testing found no protein binding drug interaction between digoxin and meloxicam.

Furosemide

Clinical studies, as well as post-marketing observations, have shown that Anti-Inflammatory Drugs">NSAIDs can reduce the natriuretic effect of furosemide and thiazide diuretics in some patients. This effect has been attributed to inhibition of renal prostaglandin synthesis. Studies with furosemide agents and meloxicam have not demonstrated a reduction in natriuretic effect. Furosemide single and multiple dose pharmacodynamics and pharmacokinetics are not affected by multiple doses of meloxicam. Nevertheless, during concomitant therapy with furosemide and Mobic, patients should be observed closely for signs of declining renal function (see PRECAUTIONS, Renal Effects), as well as to assure diuretic efficacy.

Lithium

In clinical trials, Anti-Inflammatory Drugs">NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. In a study conducted in healthy subjects, mean pre-dose lithium concentration and AUC were increased by 21% in subjects receiving lithium doses ranging from 804 to 1072 mg BID with meloxicam 15 mg QD as compared to subjects receiving lithium alone. These effects have been attributed to inhibition of renal prostaglandin synthesis by Mobic. Patients on lithium treatment should be closely monitored when Mobic is introduced or withdrawn.

Methotrexate

A study in 13 rheumatoid arthritis (RA) patients evaluated the effects of multiple doses of meloxicam on the pharmacokinetics of methotrexate taken once weekly. Meloxicam did not have a significant effect on the pharmacokinetics of single doses of methotrexate. In vitro, methotrexate did not displace meloxicam from its human serum binding sites.

Warfarin

Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing Mobic therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding. The effect of meloxicam on the anticoagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of warfarin that produced an INR (International Normalized Ratio) between 1.2 and 1.8. In these subjects, meloxicam did not alter warfarin pharmacokinetics and the average anticoagulant effect of warfarin as determined by prothrombin time. However, one subject showed an increase in INR from 1.5 to 2.1. Caution should be used when administering Mobic with warfarin since patients on warfarin may experience changes in INR and an increased risk of bleeding complications when a new medication is introduced.

Taking Mobic during Pregnancy or Breast-feeding

Mobic has been shown to cause harm to the human fetus. If you plan on becoming pregnant, discuss with your doctor the benefits and risks of using this medicine during pregnancy. It is unknown if this medicine is excreted in breast milk. If you are or will be breast feeding while you are using this medicine, check with your doctor or pharmacist to discuss the risks to your baby.

Storing Mobic

Store at 25°C (77°F); excursions permitted to 15°C - 30°C (59°F - 86°F). Keep in a dry place.

Mobic Clinical Trials and Studies

Mobic Warnings

Mobic Pill Identification / ID and Appearance

Mobic is the brand name of your medicine. The tablets are pale-yellow, round uncoated tablets, marked 59D on one side with break bar, and company logo on the other.

Mobic come in packets of blisters containing 10 and 30 tablets.

Mobic is available only with a doctor's prescription.

Articles and information related to Mobic

Edema